NCT06753721View on ClinicalTrials.gov

An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 1, 2027

Conditions
Advanced Colorectal Adenocarcinoma
Interventions
DRUG

Doxorubicin liposome combined with CapOX and Bevacizumab

Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT06753721 - An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation. | Biotech Hunter | Biotech Hunter